Company to operate as a standalone entity and
remain headquartered in Montréal
- Dialogue shareholders to receive $5.15 per share in all-cash
transaction
- Purchase price represents a premium of 43.1% to Dialogue's
closing share price on July 25, 2023,
and a premium of approximately 59.4% to the 20-day volume-weighted
average trading price of the Common Shares and is also above the
52-week high as of the same date
- Dialogue's Board of Directors (excluding any director not
entitled to vote), after receiving financial and legal advice and
the unanimous recommendation of the Strategic Committee,
unanimously recommends that shareholders vote in favour of the
Transaction
- Dialogue to maintain its head office in Montréal and
operate as a standalone entity as part of Sun Life
Canada
- Management team, including founding shareholders Cherif
Habib and Alexis Smirnov, to roll a
portion of their equity ownership and remain in their current
roles
- Dialogue to continue executing its business plan and serving
its partners and customers, each of which will continue to have
access to Dialogue's services and capabilities, and will benefit
from the continued innovation resulting from the combined strengths
of both organizations
MONTRÉAL, July 26,
2023 /CNW/ - Dialogue Health Technologies Inc.
("Dialogue" or the "Company") (TSX: CARE),
Canada's premier health and
wellness virtual care platform, announced today that it has entered
into a definitive arrangement agreement (the "Agreement")
with Sun Life Financial Inc. ("Sun Life"), pursuant to which
Sun Life will indirectly acquire all of the issued and outstanding
common shares of the Company (the "Common Shares"),
other than those owned by Sun Life Assurance Company of
Canada ("SLA") and certain
Common Shares owned by members of Dialogue management
(collectively, the "Rolling Shareholders") (the
"Transaction") for $5.15 in
cash per Common Share (the "Consideration").
![Dialogue logo (CNW Group/Dialogue Health Technologies Inc.) Dialogue logo (CNW Group/Dialogue Health Technologies Inc.)](https://mma.prnewswire.com/media/2161870/Dialogue_Health_Technologies_Inc__Dialogue_to_be_Acquired_by_Sun.jpg)
The Consideration represents a premium of approximately 43.1% to
the closing price of the Common Shares on the Toronto Stock
Exchange (the "TSX") on July 25,
2023, and a premium of approximately 59.4% to the 20-day
volume-weighted average trading price of the Common Shares on the
TSX as at the same date. The Consideration is also above the
52-week high closing price of the Common Shares on the TSX as at
July 25, 2023. The Consideration
implies an equity value for Dialogue of approximately
$365 million, as calculated on a fully diluted basis.
The Transaction emerged from a strategic review process
undertaken by the Company. The process and negotiation of the
Transaction with Sun Life were supervised by a committee of
independent directors (the "Strategic Committee"). The
Transaction has been approved unanimously by the Board of Directors
of Dialogue (the "Board") (with interested and
non-independent directors abstaining from voting) following the
unanimous recommendation of the Strategic Committee. Both the Board
and the Strategic Committee determined, after receiving financial
and legal advice, that the Transaction is in the best interests of
the Company and is fair, from a financial point of view, to
Dialogue shareholders (the "Shareholders") (other than SLA
and the Rolling Shareholders).
The acquisition of Dialogue by Sun Life is highly complementary
and beneficial to the two organizations as they share a purpose of
helping Canadians live healthier lives. As the premier integrated
health platform in Canada, with a
distinctive management team and entrepreneurial culture, Dialogue
will fit naturally as a core strategic pillar of Sun Life Canada.
Importantly, Dialogue will continue to execute its strategic plan
and grow its business. Furthermore, Dialogue will continue to
provide a premium service to all its customers and distribution
partners, each of which will continue to have access to Dialogue's
services and capabilities, and will benefit from the continued
innovation resulting from the combined strengths of both
organizations.
"In recent years, Dialogue has developed a strong relationship
with Sun Life. This transaction represents an attractive
opportunity for the Company's stakeholders. As a standalone entity
backed by Sun Life, Dialogue will have more resources to deliver on
our mission of helping people improve their health and well-being,
and the flexibility to continue to deliver on our mission by
leveraging the respective strengths of both organizations. We are
enthusiastic about the prospects of this next chapter in Dialogue's
history," said Cherif Habib, Chief Executive Officer of
Dialogue.
"This is a natural step forward in Sun Life's relationship with
Dialogue, having first invested in the Company in 2020 and
subsequently expanding our relationship as a large shareholder and
partner. Sun Life has a high regard for the exceptional
organization that the team at Dialogue has built. We are excited to
work alongside its employees to continue developing the Company.
Dialogue and Sun Life are perfectly aligned in our commitment to
provide innovative digital solutions to support the health care
needs of Canadians. We look forward to collaborating with Dialogue
in the years ahead to unlock more innovative solutions to empower
Canadians on their health journey," said Jacques Goulet, President of Sun Life
Canada.
"It's been an honour to be part of the Dialogue story since it
was conceived as the first company in our venture builder, Diagram.
Today is another exciting milestone for this innovative Montréal,
Québec and Canada success story
that now has over 900 employees and practitioners, and is available
to over 6 million Canadians," said Paul Desmarais III, Chairman & CEO of
Sagard and outgoing Chairman of
Dialogue. "I am proud of the positive impact Dialogue has
had in improving access to healthcare and modernizing the B2B
healthcare space.
Dialogue will maintain its head office in Montréal, Québec, and
will continue to operate as a standalone entity of Sun Life Canada,
with oversight from a new board of directors comprised of senior
executives from Sun Life and Dialogue. The Transaction is not
subject to any financing condition and is expected to close in the
fourth quarter of 2023, subject to obtaining the required
Shareholder, court and regulatory approvals, and the satisfaction
of other customary closing conditions.
In connection with the Transaction, Portag3 Ventures LP, Portag3
Ventures II Investments LP and WSC IV LP (collectively,
the "Supporting Shareholders"), collectively holding
approximately 21.0% of the outstanding Common Shares, and each of
the directors and executive officers of the Company have entered
into voting and support agreements pursuant to which they have
agreed to vote their Common Shares in favour of the Transaction.
Consequently, shareholders holding approximately 30.5% of the
Common Shares eligible to vote in the "majority of the minority"
vote described below have agreed to vote in favour of the
Transaction.
Transaction Rationale
The conclusions and recommendations of the Strategic Committee
and the Board have been based on a number of factors, including the
following:
- Compelling Value and Immediate Liquidity to
Shareholders: The all-cash Consideration provides Shareholders
with certainty of value and immediate liquidity. The Consideration
to be received by Shareholders pursuant to the Transaction
represents a 43.1% premium to the closing price of the Common
Shares on the TSX on July 25, 2023,
and a 59.4% premium to the 20-day volume-weighted average trading
price of the Common Shares on the TSX as at July 25, 2023. The Consideration to be received
by Shareholders pursuant to the Transaction is also above the
52-week high closing price of the Common Shares on the TSX as at
July 25, 2023;
- Highest Proposal following Market Check: The Transaction
is the result of a strategic review process undertaken by the
Company. With the assistance of its financial advisor, and the
oversight of the Strategic Committee, comprised of independent
directors, the Company conducted a market check after the receipt
of an initial proposal from Sun Life and contacted various
potential financial and strategic purchasers across North America, following which the offer by
Sun Life emerged as the highest proposal;
- Arrangement Agreement Terms: The terms of the Agreement
were negotiated with oversight and participation of the Strategic
Committee and the assistance of Dialogue's external financial and
legal advisors. Such terms are reasonable in the judgment of the
Strategic Committee and the Board and include a customary
"fiduciary out" provision that entitles the Board to consider and,
subject to certain conditions, including Sun Life's right to match
and the payment of a reasonable termination fee, accept a superior
proposal in certain circumstances;
- Fairness Opinions: The Strategic Committee and the Board
received verbal fairness opinions from each of National Bank
Financial Inc. ("National Bank Financial") and Scotia
Capital Inc. ("Scotiabank"), which each concluded that,
based upon and subject to the assumptions, limitations and
qualifications set out in their respective opinions, as at the date
hereof, the Consideration to be received by the Shareholders (other
than SLA and the Rolling Shareholders) pursuant to the Transaction
is fair, from a financial point of view, to such Shareholders. The
fairness opinions will be included in the management information
circular to be mailed to Shareholders in connection with the
special meeting of the Shareholders (the "Meeting") to
approve the Transaction; and
- Commitments to Employees: Sun Life has agreed to certain
covenants regarding employees of the Company, including to honour
and comply with the terms of all employment and other agreements
with the Company's employees. Both Sun Life and management of the
Company are committed to employee retention and well-being.
Minority Vote and Court
Approval
The Transaction must be approved by two-thirds of the votes cast
by Shareholders, as well as a majority of the votes cast by
Shareholders other than SLA and the Rolling Shareholders in
accordance with Multilateral Instrument 61-101 – Protection of
Minority Security Holders in Special Transactions ("MI
61-101"), and by the Superior Court of Québec, which will
consider the fairness and reasonableness of the Transaction to all
Shareholders.
Fairness Opinions
In connection with their review and consideration of the
Transaction, the Strategic Committee engaged National Bank
Financial as its financial advisor in respect of the Transaction
and Scotiabank as its independent financial advisor in respect of
the Transaction. Both National Bank Financial and Scotiabank
provided a verbal opinion to the Board and Strategic Committee
that, as at the date hereof and based upon and subject to the
assumptions, limitations and qualifications set out in their
respective opinions, the Consideration to be received by the
Shareholders (other than SLA and the Rolling Shareholders) pursuant
to the Transaction is fair, from a financial point of view, to such
Shareholders.
Additional Transaction
Details
The Transaction is to be completed by way of a statutory plan of
arrangement under the Canada Business Corporations Act and will
constitute a "business combination" for purposes of MI 61-101. The
Transaction is subject to certain approvals at the Meeting,
including by: (i) at least two-thirds of the votes cast by
Shareholders voting in person or by proxy, voting together as a
single class; and (ii) a simple majority of the votes cast by
Shareholders (other than SLA and the Rolling Shareholders) voting
in person or by proxy, voting together as a single class. For the
purposes of the "majority of the minority" approval requirement
under MI 61-101, the votes cast in respect of the Transaction by
the Rolling Shareholders and SLA, who hold, in the aggregate,
approximately 31.3% of the outstanding Common Shares, will be
excluded. The parties are relying on the "previous arm's length
negotiations" exemption from the formal valuation requirements of
MI 61-101, in section 4.4(1)(b), on the basis that: (i) the
consideration per Common Share to be received by the Shareholders
(other than SLA and the Rolling Shareholders) under the Transaction
is at least equal in value to and is in the same form as the
highest consideration agreed to with the Supporting Shareholders in
arm's length negotiations in connection with the Transaction, (ii)
as at the date of the voting and support agreements, at least one
of the Supporting Shareholders beneficially owned or exercised
control or direction over, and agreed to sell, at least 10% of the
then outstanding Common Shares, and at least one or more of the
Supporting Shareholders exercised control or direction over, and
agreed to sell, in the aggregate, at least 20% of the then
outstanding Common Shares not beneficially owned or over which
control or direction is exercised by Sun Life and any persons
acting jointly or in concert with Sun Life, (iii) Sun Life
reasonably believes, after reasonable inquiry, that at the time of
entering into the voting and support agreements, the Supporting
Shareholders had full knowledge of and access to information
concerning the Company and its securities, and any factors peculiar
to the Supporting Shareholders, including non-financial factors,
that were considered relevant by the Supporting Shareholders in
assessing the consideration did not have the effect of reducing the
price that would otherwise have been considered acceptable by the
Supporting Shareholders, (iv) at the time of entering into the
voting and support agreements, Sun Life did not know of any
material information in respect of Dialogue or the Common Shares
that had not been generally disclosed, and that, if disclosed,
could have reasonably been expected to increase the agreed
consideration, and (v) since the time of entering into the voting
and support agreements and as of the date hereof, Sun Life does not
know, after reasonable inquiry, of any material information in
respect of Dialogue or the Common Shares that has not been
generally disclosed and could reasonably be expected to increase
the value of the Common Shares.
The Agreement includes representations, warranties and
covenants, including customary provisions relating to
non-solicitation and "fiduciary out" provisions that entitle the
Board to consider and, subject to certain conditions, including Sun
Life's right to match, accept a superior proposal. A termination
fee of $12 million will be payable by Dialogue to Sun Life in
certain circumstances, including if the Company terminates the
Agreement to accept a superior proposal after Sun Life fails to
exercise its match right.
The Rolling Shareholders have agreed to roll a portion of their
Common Shares (including the Common Shares issuable on the exercise
of incentive awards or subscribed for using the proceeds received
therefrom) (the "Rollover Shares") and maintain a minority
interest in Dialogue following closing. The Rollover Shares will
represent approximately 2.6% of the issued and outstanding Common
Shares immediately prior to the completion of the Transaction.
Upon closing of the Transaction, Sun Life intends to cause the
Common Shares to be delisted from the TSX and to cause the Company
to submit an application to cease to be a reporting issuer under
applicable Canadian securities laws.
Additional details regarding the terms and conditions of the
Transaction, the rationale for the recommendations made by the
Strategic Committee and the Board, and the fairness opinions, and
how Shareholders can participate in and vote at the Meeting, will
be set out in Dialogue's management information circular to be
prepared and made available to Shareholders in connection with the
Meeting. Copies of the Agreement, the forms of voting and support
agreements, the management information circular and proxy materials
in respect of the Meeting will be filed by the Company under its
profile on SEDAR at www.sedar.com.
Advisors
National Bank Financial is acting as exclusive financial advisor
to Dialogue and financial advisor to the Strategic Committee, and
has provided a fairness opinion to Dialogue's Board of Directors
and the Strategic Committee. Scotiabank is acting as independent
financial advisor to the Strategic Committee and has provided a
fairness opinion to the Strategic Committee. Osler, Hoskin & Harcourt LLP is acting as
legal advisor to Dialogue. Stikeman Elliott LLP is acting as legal
advisor to the Rolling Shareholders.
About Dialogue
Incorporated in 2016, Dialogue is Canada's premier virtual healthcare and
wellness platform, providing affordable, on-demand access to
quality care. Through its team of health professionals, it serves
employers and organizations who have an interest in the health and
well-being of their employees, members and their families.
Dialogue's Integrated Health Platform™ is a one-stop healthcare hub
that centralizes all programs in a single, user-friendly
application, providing access to services 24 hours per day, 365
days per year from the convenience of a smartphone, computer or
tablet. Dialogue is the first virtual care provider to receive the
Accreditation Canada Primer award, a third-party validation of
safety and high-level quality of care. For more information, please
visit the Company's website at www.dialogue.co.
About Sun Life
Sun Life is a leading international financial services
organization providing asset management, wealth, insurance and
health solutions to individual and institutional clients. Sun Life
has operations in a number of markets worldwide, including
Canada, the United States, the United Kingdom, Ireland, Hong
Kong, the Philippines,
Japan, Indonesia, India, China,
Australia, Singapore, Vietnam, Malaysia and Bermuda. As of March
31, 2023, Sun Life had total assets under management of
$1.36 trillion.
Sun Life trades on the Toronto
(TSX), New York (NYSE) and
Philippine (PSE) stock exchanges under the ticker symbol SLF.
SLA is a wholly-owned subsidiary of Sun Life. SLA is organized
under the Insurance Companies Act (Canada).
Forward-Looking
Information
This release includes "forward-looking information" and
"forward-looking statements" (collectively, "forward-looking
statements") within the meaning of applicable securities laws.
Forward-looking statements include, but are not limited to,
statements with respect to the rationale of the Board for entering
into the Agreement, the terms and conditions of the Agreement, the
premium to be received by Shareholders, the expected benefits of
the Transaction, the anticipated timing and the various steps to be
completed in connection with the Transaction, including receipt of
Shareholder, court and regulatory approvals, the anticipated timing
for closing of the Transaction, the anticipated delisting of the
Common Shares from the TSX and the Company ceasing to be a
reporting issuer under Canadian securities laws.
In some cases, but not necessarily in all cases, forward-looking
statements can be identified by the use of forward-looking
terminology such as "plans" "targets", "expects" or "does not
expect", "is expected", "an opportunity exists", "is positioned",
"estimates", "intends", "assumes", "anticipates" or "does not
anticipate" or "believes", or variations of such words and phrases
or state that certain actions, events or results "may", "could",
"would", "might", "will" or "will be taken", "occur" or "be
achieved". In addition, any statements that refer to expectations,
projections or other characterizations of future events or
circumstances contain forward-looking statements. Forward-looking
statements are not historical facts, nor guarantees or assurances
of future performance but instead represent management's current
beliefs, expectations, estimates and projections regarding future
events and operating performance.
Forward-looking statements are necessarily based on a number of
opinions, assumptions and estimates that, while considered
reasonable by Dialogue as of the date of this release, are subject
to inherent uncertainties, risks and changes in circumstances that
may differ materially from those contemplated by the
forward-looking statements. Important factors that could cause
actual results to differ, possibly materially, from those indicated
by the forward-looking statements include, but are not limited to,
the possibility that the proposed Transaction will not be completed
on the terms and conditions, or on the timing, currently
contemplated, or at all, the possibility of the Agreement being
terminated in certain circumstances, the ability of the Board to
consider and approve a superior proposal for the Company, and the
other risk factors identified under "Risk Factors" in Dialogue's
latest annual information form and management's discussion and
analysis for the year ended December 31,
2022, and in other periodic filings that Dialogue has made
and may make in the future with the securities commissions or
similar regulatory authorities in Canada, all of which are available under
Dialogue's SEDAR profile at www.sedar.com. These factors are not
intended to represent a complete list of the factors that could
affect Dialogue. However, such risk factors should be considered
carefully. There can be no assurance that such estimates and
assumptions will prove to be correct. You should not place undue
reliance on forward-looking statements, which speak only as of the
date of this release.
Although Dialogue has attempted to identify important risk
factors that could cause actual results to differ materially from
those contained in forward-looking statements, there may be other
risk factors not currently known to us or that we currently believe
are not material that could also cause actual results or future
events to differ materially from those expressed in such
forward-looking statements. There can be no assurance that such
information will prove to be accurate, as actual results and future
events could differ materially from those anticipated in such
information. Accordingly, you should not place undue reliance on
forward-looking statements. The forward-looking statements
represent Dialogue's expectations as of the date of this release
(or as the date it is otherwise stated to be made) and are subject
to change after such date. However, Dialogue disclaims any
intention and undertakes no obligation to update or revise any
forward-looking statements whether as a result of new information,
future events or otherwise, except as required under applicable
Canadian securities laws. All of the forward-looking statements
contained in this release are expressly qualified by the foregoing
cautionary statements.
SOURCE Dialogue Health Technologies Inc.